This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wong, S. J. Articles by Chitambar, C. R. Search for Related Content PubMed PubMed Citation Articles by Wong, S. J. Articles by Chitambar, C. R.

Increased Sensitivity of Hydroxyurea-resistant Leukemic Cells to Gemcitabine¹

Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin 53226

ABSTRACT

Tumor cell resistance to certain chemotherapeutic agents may result in cross-resistance to related antineoplastic agents. To study cross-resistance among inhibitors of ribonucleotide reductase, we developed hydroxyurea-resistant (HU-R) CCRF-CEM cells. These cells were 6-fold more resistant to hydroxyurea than the parent hydroxyurea-sensitive (HU-S) cell line and displayed an increase in the mRNA and protein of the R2 subunit of ribonucleotide reductase. We examined whether HU-R cells were cross-resistant to gemcitabine, a drug that blocks cell proliferation by inhibiting ribonucleotide reductase and incorporating itself into DNA. Contrary to our expectation, HU-R cells had an increased sensitivity to gemcitabine. The IC₅₀ of gemcitabine was 0.061 ± 0.03 µM for HU-R cells versus 0.16 ± 0.02 µM for HU-S cells (P = 0.005). The cellular uptake of [³H]gemcitabine and its incorporation into DNA were increased in HU-R cells. Over an 18-h incubation with radiolabeled gemcitabine (0.25 µM), gemcitabine uptake was 286 ± 37.3 fmol/10⁶ cells for HU-R cells and 128 ± 8.8 fmol/10⁶ cells for HU-S cells (P = 0.03). The incorporation of gemcitabine into DNA was 75 ± 6.7 fmol/10⁶ cells for HU-R cells versus 22 ± 0.6 fmol/10⁶ cells for HU-S cells (P < 0.02). Our studies suggest that the increased sensitivity of HU-R cells to gemcitabine results from increased drug uptake by these cells. This, in turn, favors the incorporation of gemcitabine into DNA, resulting in enhanced cytotoxicity. The increased sensitivity of malignant cells to gemcitabine after the development of hydroxyurea resistance may be relevant to the design of chemotherapeutic trials with these drugs.

This article has been cited by other articles:

				D. A. Green, W. E. Antholine, S. J. Wong, D. R. Richardson, and C. R. Chitambar Inhibition of Malignant Cell Growth by 311, a Novel Iron Chelator of the Pyridoxal Isonicotinoyl Hydrazone Class: Effect on the R2 subunit of Ribonucleotide Reductase Clin. Cancer Res., November 1, 2001; 7(11): 3574 - 3579. [Abstract] [Full Text] [PDF]